Table 3.
Cox Regression Results Indicating Main Effects for Intervention and Medication
| Outcome | Model 1* | Model 2*,† | ||
|---|---|---|---|---|
| HR (95% CI) | p Value | HR (95% CI) | p Value | |
| MMD | ||||
| Intervention (PA vs HE) | 0.81 (0.69, 0.97) | .019 | 0.84 (0.71, 1.00) | .049 |
| Medication use | <.001 | .048 | ||
| ACEi use versus no use | 1.77 (1.35, 2.32) | 1.43 (1.07, 1.91) | ||
| Other use versus no use | 1.46 (1.12, 1.88) | 1.26 (0.96, 1.65) | ||
| Persistent MMD | ||||
| Intervention (PA vs HE) | 0.72 (0.57, 0.91) | .006 | 0.75 (0.59, 0.95) | .017 |
| Medication use | <.001 | .004 | ||
| ACEi use versus no use | 2.36 (1.58, 3.52) | 2.00 (1.31, 3.04) | ||
| Other use versus no use | 1.77 (1.20, 2.61) | 1.56 (1.04, 2.34) | ||
Notes: ACE = angiotensin-converting enzyme; CI = confidence interval; HE, health education; HR = hazard ratio; MMD = major mobility disability; PA = physical activity.
*Hazards for disability outcomes stratified by sex and clinical site.
†Includes adjustment for baseline covariates including Short Physical Performance Battery score and a composite index of comorbid conditions reported previously (13,22).